FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200403778> ?p ?o ?g. }

• W4200403778 endingPage "199" @default.
• W4200403778 startingPage "191" @default.
• W4200403778 abstract "The national clinical guidelines for the treatment of novel coronavirus infection (COVID-19) are the main source of information and the reference point for clinical decision-making by healthcare professionals in the Kyrgyz Republic. The recommendations presented in these documents are largely based on data from real clinical practice, but the efficacy and safety of a number of antiviral agents, the indications for which have been expanded to include COVID-19 treatment, remain unclear. The aim of the study was to conduct a retrospective pharmacoepidemiological analysis of lopinavir+ritonavir use in hospitals in the Kyrgyz Republic for the treatment of COVID-19 during the period from March until April 2020. Materials and methods: the paper describes a retrospective study of 145 medical records of patients with confirmed COVID-19 who were hospitalized in infectious disease departments/hospitals of the Kyrgyz Republic. Statistical processing was performed using Microsoft Excel 2017. Results: between 16 March 2020 and 25 April 2020, 145 patients were prescribed lopinavir+ritonavir at a dose of 200 mg + 50 mg, 2 tablets twice a day—in line with the dosage regimen recommended by the national guideline. The national guideline recommended the treatment duration of 10 days, while the actual treatment duration was 1–12 days (5.5 days on average) depending on the tolerability of the drug. The use of the drug was accompanied by adverse drug reactions (ADRs) in 78 patients (53.8%), and caused deterioration in the general condition of 73 of these patients (94.8%) which resulted in discontinuation of the drug. The most common ADRs were nausea, vomiting, diarrhoea, decreased appetite, yellowness of the skin, and, according to laboratory studies, an increase in serum levels of bilirubin, creatinine, glucose, aspartate aminotransferase and amylase activity. A retrospective assessment of the causal relationship probability according to the Naranjo scale showed an interrelation between the use of lopinavir+ritonavir and ADR development. Conclusions: the use of the lopinavir+ritonavir drug in COVID-19 patients led to deterioration of their general condition, which was severe in some cases. The data obtained indicate that the use of this drug for COVID-19 treatment is clinically unreasonable and irrational. Lopinavir+ritonavir was excluded from subsequent revisions of the clinical guidelines for the diagnosis and treatment of COVID-19 in the Kyrgyz Republic." @default.
• W4200403778 created "2021-12-31" @default.
• W4200403778 creator A5023114678 @default.
• W4200403778 creator A5036872776 @default.
• W4200403778 date "2021-12-09" @default.
• W4200403778 modified "2023-09-27" @default.
• W4200403778 title "Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan" @default.
• W4200403778 cites W2139603860 @default.
• W4200403778 cites W2150120685 @default.
• W4200403778 cites W3007969569 @default.
• W4200403778 cites W3008131087 @default.
• W4200403778 cites W3009828946 @default.
• W4200403778 cites W3020473828 @default.
• W4200403778 cites W3023215109 @default.
• W4200403778 cites W3041998307 @default.
• W4200403778 cites W3043504361 @default.
• W4200403778 doi "https://doi.org/10.30895/2312-7821-2021-9-4-191-199" @default.
• W4200403778 hasPublicationYear "2021" @default.
• W4200403778 type Work @default.
• W4200403778 citedByCount "0" @default.
• W4200403778 crossrefType "journal-article" @default.
• W4200403778 hasAuthorship W4200403778A5023114678 @default.
• W4200403778 hasAuthorship W4200403778A5036872776 @default.
• W4200403778 hasBestOaLocation W42004037781 @default.
• W4200403778 hasConcept C126322002 @default.
• W4200403778 hasConcept C142462285 @default.
• W4200403778 hasConcept C142724271 @default.
• W4200403778 hasConcept C159047783 @default.
• W4200403778 hasConcept C167135981 @default.
• W4200403778 hasConcept C177713679 @default.
• W4200403778 hasConcept C187212893 @default.
• W4200403778 hasConcept C194828623 @default.
• W4200403778 hasConcept C197934379 @default.
• W4200403778 hasConcept C2777182164 @default.
• W4200403778 hasConcept C2778375690 @default.
• W4200403778 hasConcept C2778715236 @default.
• W4200403778 hasConcept C2779134260 @default.
• W4200403778 hasConcept C2779298103 @default.
• W4200403778 hasConcept C2780182762 @default.
• W4200403778 hasConcept C2781413609 @default.
• W4200403778 hasConcept C2993143319 @default.
• W4200403778 hasConcept C3008058167 @default.
• W4200403778 hasConcept C3013748606 @default.
• W4200403778 hasConcept C524204448 @default.
• W4200403778 hasConcept C71924100 @default.
• W4200403778 hasConcept C89623803 @default.
• W4200403778 hasConceptScore W4200403778C126322002 @default.
• W4200403778 hasConceptScore W4200403778C142462285 @default.
• W4200403778 hasConceptScore W4200403778C142724271 @default.
• W4200403778 hasConceptScore W4200403778C159047783 @default.
• W4200403778 hasConceptScore W4200403778C167135981 @default.
• W4200403778 hasConceptScore W4200403778C177713679 @default.
• W4200403778 hasConceptScore W4200403778C187212893 @default.
• W4200403778 hasConceptScore W4200403778C194828623 @default.
• W4200403778 hasConceptScore W4200403778C197934379 @default.
• W4200403778 hasConceptScore W4200403778C2777182164 @default.
• W4200403778 hasConceptScore W4200403778C2778375690 @default.
• W4200403778 hasConceptScore W4200403778C2778715236 @default.
• W4200403778 hasConceptScore W4200403778C2779134260 @default.
• W4200403778 hasConceptScore W4200403778C2779298103 @default.
• W4200403778 hasConceptScore W4200403778C2780182762 @default.
• W4200403778 hasConceptScore W4200403778C2781413609 @default.
• W4200403778 hasConceptScore W4200403778C2993143319 @default.
• W4200403778 hasConceptScore W4200403778C3008058167 @default.
• W4200403778 hasConceptScore W4200403778C3013748606 @default.
• W4200403778 hasConceptScore W4200403778C524204448 @default.
• W4200403778 hasConceptScore W4200403778C71924100 @default.
• W4200403778 hasConceptScore W4200403778C89623803 @default.
• W4200403778 hasIssue "4" @default.
• W4200403778 hasLocation W42004037781 @default.
• W4200403778 hasLocation W42004037782 @default.
• W4200403778 hasOpenAccess W4200403778 @default.
• W4200403778 hasPrimaryLocation W42004037781 @default.
• W4200403778 hasRelatedWork W1931895424 @default.
• W4200403778 hasRelatedWork W1933596914 @default.
• W4200403778 hasRelatedWork W1998564612 @default.
• W4200403778 hasRelatedWork W2009822178 @default.
• W4200403778 hasRelatedWork W2014051152 @default.
• W4200403778 hasRelatedWork W2043317290 @default.
• W4200403778 hasRelatedWork W2792428998 @default.
• W4200403778 hasRelatedWork W4316469773 @default.
• W4200403778 hasRelatedWork W4318478878 @default.
• W4200403778 hasRelatedWork W1191760561 @default.
• W4200403778 hasVolume "9" @default.
• W4200403778 isParatext "false" @default.
• W4200403778 isRetracted "false" @default.
• W4200403778 workType "article" @default.